These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 18158966

  • 21. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
    Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK.
    Blood; 2003 Sep 15; 102(6):2292-9. PubMed ID: 12763937
    [Abstract] [Full Text] [Related]

  • 22. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S, Nijmeijer BA, van Schie ML, Salvatori DC, Maas S, Griffioen M, Falkenburg JH.
    Biol Blood Marrow Transplant; 2013 Jun 15; 19(6):867-75. PubMed ID: 23500532
    [Abstract] [Full Text] [Related]

  • 23. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M, Bartsch K, Tschiedel S, Niederwieser D.
    Dtsch Med Wochenschr; 2008 Jul 15; 133(28-29):1511-6. PubMed ID: 18597211
    [Abstract] [Full Text] [Related]

  • 24. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
    Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M, Cignetti A.
    Int Immunol; 2008 Jul 15; 20(7):841-8. PubMed ID: 18469328
    [Abstract] [Full Text] [Related]

  • 25. Large-scale generation of human allodepleted anti-3rd party lymphocytes.
    De Ioanni M, Di Ianni M, Bonifacio E, Moretti L, Cecchini D, Bazzucchi F, Terenzi A, Aloisi T, Falzetti F, Aversa F, Reisner Y, Martelli MF, Tabilio A.
    Blood Cells Mol Dis; 2008 Jul 15; 40(1):106-12. PubMed ID: 17931916
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
    Morecki S, Yacovlev E, Gelfand Y, Shabat Y, Slavin S.
    Biol Blood Marrow Transplant; 2009 Apr 15; 15(4):406-15. PubMed ID: 19285627
    [Abstract] [Full Text] [Related]

  • 31. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
    Levenga H, Woestenenk R, Schattenberg AV, Maas F, Jansen JH, Raymakers R, De Mulder PH, van de Wiel-van Kemenade E, Schaap N, de Witte T, Dolstra H.
    Bone Marrow Transplant; 2007 Sep 15; 40(6):585-92. PubMed ID: 17637687
    [Abstract] [Full Text] [Related]

  • 32. Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation.
    André-Schmutz I, Dal Cortivo L, Fischer A, Cavazzana-Calvo M.
    Cytotherapy; 2005 Sep 15; 7(2):102-8. PubMed ID: 16040389
    [Abstract] [Full Text] [Related]

  • 33. Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia.
    Nijmeijer BA, van Schie ML, Verzaal P, Willemze R, Falkenburg JH.
    Exp Hematol; 2005 Oct 15; 33(10):1172-81. PubMed ID: 16219539
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
    Sprangers B, Van Wijmeersch B, Fevery S, Waer M, Billiau AD.
    Nat Clin Pract Oncol; 2007 Jul 15; 4(7):404-14. PubMed ID: 17597705
    [Abstract] [Full Text] [Related]

  • 36. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander AR, Fehse B, Bokemeyer C, Kroger N.
    Haematologica; 2008 Mar 15; 93(3):423-30. PubMed ID: 18287134
    [Abstract] [Full Text] [Related]

  • 37. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B, Kruisselbrink AB, Frederik Falkenburg JH, Jedema I.
    Biol Blood Marrow Transplant; 2014 Jun 15; 20(6):760-9. PubMed ID: 24607556
    [Abstract] [Full Text] [Related]

  • 38. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.
    Bastien JP, Roy J, Roy DC.
    Semin Oncol; 2012 Dec 15; 39(6):674-82. PubMed ID: 23206844
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG.
    Biol Blood Marrow Transplant; 2009 Jan 15; 15(1):61-72. PubMed ID: 19135944
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.